Efficacy and Safety of Drug Combinations for Chronic Pelvic Pain: Protocol for a Systematic Review.
Efficacy and Safety of Drug Combinations for Chronic Pelvic Pain: Protocol for a Systematic Review.
复制标题
DOI：
10.2196/21909
复制
发表时间：
2021-05-17
影响因子：
1.7
通讯作者：
Gilron I
中科院分区：
文献类型：
--
作者：
Mohiuddin M;Park R;Wesselmann U;Pukall C;Jarvi K;Nickel C;Doiron C;Gilron I
慢性盆腔疼痛具有各种病因和机制，影响男性和女性，是一个主要的挑战。单一疗法对慢性盆腔疼痛往往不成功，为了改善结果，经常联合使用不同类别的药物。虽然已经报道了一些治疗慢性盆腔疼痛的联合试验，但我们还没有意识到任何关于联合药物治疗慢性盆腔疼痛的现有证据的系统评价。我们已经制定了一项系统回顾的方案，以评估联合用药治疗慢性盆腔疼痛的有效性和安全性的现有证据。这项系统化的综述将涉及对随机对照试验的详细搜索，这些试验研究的是治疗成人慢性盆腔疼痛的药物组合。搜索的数据库将包括Cochrane中央对照试验登记(CENTAL)、MEDLINE和EMBASE，从它们开始到进行搜索以确定相关研究的日期。主要结果将是使用经过验证的评分工具测量疼痛缓解。在报告的次要结果中，将包括以下内容：不良事件、严重不良事件、性功能、生活质量以及抑郁和焦虑。每项纳入研究的方法学质量将使用Cochrane偏差风险工具进行评估。由该协议定义的系统综述有望综合现有的关于联合药物治疗慢性盆腔疼痛的高质量证据，这可能有助于指导患者及其卫生保健提供者未来的研究和治疗选择。这篇综述将使人们更清楚地了解联合药物治疗慢性盆腔疼痛的有效性和安全性。PROSPERO国际前瞻性系统评价登记簿CRD42020192231；https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=192231 PRR1-10.2196/2231
Chronic pelvic pain with various etiologies and mechanisms affects men and women and is a major challenge. Monotherapy is often unsuccessful for chronic pelvic pain, and combinations of different classes of medications are frequently prescribed, with the expectation of improved outcomes. Although a number of combination trials for chronic pelvic pain have been reported, we are not aware of any systematic reviews of the available evidence on combination drug therapy for chronic pelvic pain. We have developed a protocol for a systematic review to evaluate available evidence of the efficacy and safety of drug combinations for chronic pelvic pain. This systematic review will involve a detailed search of randomized controlled trials investigating drug combinations to treat chronic pelvic pain in adults. The databases searched will include the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE from their inception until the date the searches are run to identify relevant studies. The primary outcome will be pain relief measured using validated scoring tools. Secondary outcomes, where reported, will include the following: adverse events, serious adverse events, sexual function, quality of life, and depression and anxiety. Methodological quality of each included study will be assessed using the Cochrane Risk of Bias Tool. The systematic review defined by this protocol is expected to synthesize available good quality evidence on combination drug therapy in chronic pelvic pain, which may help guide future research and treatment choices for patients and their health care providers. This review will provide a clearer understanding of the efficacy and safety of combination pharmacological therapy for chronic pelvic pain. PROSPERO International Prospective Register of Systematic Reviews CRD42020192231; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=192231 PRR1-10.2196/21909
DOI：
10.1016/j.juro.2010.10.053
发表时间：
2011-03
期刊：
The Journal of urology
影响因子：
--
作者：
Yang CC;Burks DA;Propert KJ;Mayer RD;Peters KM;Nickel JC;Payne CK;FitzGerald MP;Hanno PM;Chai TC;Kreder KJ;Lukacz ES;Foster HE;Cen L;Landis JR;Kusek JW;Nyberg LM;Interstitial Cystitis Collaborative Research Network
通讯作者：
Interstitial Cystitis Collaborative Research Network